VAXCYTE INC (PCVX)

Company Profile

Vaxcyte, Inc. engages in the development of vaccines for infectious diseases. The company is headquartered in San Carlos, California and currently employs 254 full-time employees. The company went IPO on 2020-06-12. The company is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation 31-valent PCV is developed for the prevention of IPD in adults. Its pipeline also includes VAX-A1, VAX-PG, and VAX-GI. VAX-A1, a novel conjugate vaccine candidate designed to prevent disease caused by Group A Streptococcus (Group A Strep). VAX-PG, a novel protein vaccine candidate targeting pathogen responsible for periodontitis, a chronic oral inflammatory disease. VAX-GI, a novel preclinical vaccine candidate being developed as a preventative treatment for dysentery and shigellosis. Its technology platform includes advanced chemistry and the XpressCF cell-free protein synthesis platform.

Company Info

VAXCYTE INC

825 Industrial Road, Ste. 300

San Carlos CALIFORNIA 94404

P: 16508370111

CEO: Grant E. Pickering

Employees: 254

Website: https://vaxcyte.com/